General Information of Drug (ID: DMELNA8)

Drug Name
TGN-1412 Drug Info
Synonyms SuperMAB; CD28-SuperMAB; Superagonistic monoclonal antibodies, TeGenero
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMELNA8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Belatacept DMXLYQF Kidney transplant rejection NE84 Approved [3]
AB-103 DMPDQ8T Necrotizing soft tissue infection 1B71 Phase 3 [4]
Lulizumab pegol DMGWZ93 Systemic lupus erythematosus 4A40.0 Phase 2 [5]
REGN5678 DM0Y6WU Prostate cancer 2C82.0 Phase 1/2 [6]
AU101 DMLAKPI Osteosarcoma 2B51 Phase 1/2 [7]
REGN5668 DMH1UV5 Ovarian cancer 2C73 Phase 1/2 [8]
SAR442257 DMXD5QP Malignant neoplasm 2A00-2F9Z Phase 1 [9]
CD28 and CD137 CAR-T Cells DMFGQXB Acute lymphoblastic leukaemia 2A85 Phase 1 [10]
CD19-CAR and CD28-CAR T Cells DMUR1MN Acute lymphoblastic leukaemia 2A85 Phase 1 [11]
RO7443904 DMSWZNU Non-hodgkin lymphoma 2B33.5 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell-specific surface glycoprotein CD28 (CD28) TTQ13FT CD28_HUMAN Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020365)
2 TGN1412: From Discovery to Disaster. J Young Pharm. 2010 Jul-Sep; 2(3): 332-336.
3 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
9 Clinical pipeline report, company report or official report of Sanofi.
10 ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
11 ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
12 Clinical pipeline report, company report or official report of Genentch